<mods:mods version="3.3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mods="http://www.loc.gov/mods/v3"><mods:titleInfo><mods:title>RISING INCIDENCE OF FATTY LIVER DISEASE IN YOUNG ADULTS: EPIDEMIOLOGY, RISK FACTORS, AND PUBLIC HEALTH IMPLICATIONS</mods:title></mods:titleInfo><mods:name type="personal"><mods:namePart type="given">Dr. AMAN</mods:namePart><mods:namePart type="family">KHANDELWAL</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:name type="personal"><mods:namePart type="given">Sahibole</mods:namePart><mods:namePart type="family">Mohammed</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:name type="personal"><mods:namePart type="given">Zunaira</mods:namePart><mods:namePart type="family">Khan</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:abstract>Non-alcoholic fatty liver disease (NAFLD), recently rebranded as metabolic dysfunction-associated steatotic liver disease (MASLD), has emerged as one of the most pressing chronic liver conditions affecting the global population. Historically perceived as a disease of middle-aged and older adults with metabolic comorbidities, NAFLD is now increasingly diagnosed in adolescents and young adults aged 15–39 years. This demographic shift represents a significant public health concern, as early-onset hepatic steatosis provides a longer window for disease progression to non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma.</mods:abstract><mods:originInfo><mods:dateIssued encoding="iso8601">2026-05-04</mods:dateIssued></mods:originInfo><mods:originInfo><mods:publisher>Research Science and Innovation House</mods:publisher></mods:originInfo><mods:genre>Maqola</mods:genre></mods:mods>